Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Sells $423,054.66 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 9,973 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $423,054.66. Following the transaction, the chief executive officer now directly owns 180,890 shares of the company’s stock, valued at $7,673,353.80. The trade was a 5.23 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

• On Wednesday, February 19th, Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00.

CRISPR Therapeutics Trading Up 0.3 %

NASDAQ:CRSP opened at $42.12 on Friday. The firm’s fifty day simple moving average is $43.06 and its 200 day simple moving average is $45.58. CRISPR Therapeutics AG has a twelve month low of $36.52 and a twelve month high of $75.91. The firm has a market capitalization of $3.61 billion, a price-to-earnings ratio of -9.64 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wood Tarver Financial Group LLC acquired a new position in shares of CRISPR Therapeutics during the fourth quarter worth $30,000. Ameriflex Group Inc. acquired a new position in CRISPR Therapeutics in the 4th quarter worth $36,000. GF Fund Management CO. LTD. purchased a new position in CRISPR Therapeutics in the 4th quarter valued at about $71,000. Sunbelt Securities Inc. grew its stake in shares of CRISPR Therapeutics by 108.6% during the fourth quarter. Sunbelt Securities Inc. now owns 6,165 shares of the company’s stock valued at $238,000 after acquiring an additional 3,210 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of CRISPR Therapeutics by 2.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 690,191 shares of the company’s stock worth $27,166,000 after acquiring an additional 13,865 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Barclays raised their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Citigroup reduced their price target on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a research note on Tuesday, February 18th. Evercore ISI raised CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $60.00 to $99.00 in a research report on Friday, February 14th. Finally, Morgan Stanley increased their target price on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research report on Friday, February 14th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus price target of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.